September 9, 2020What's New
DPHARM is the annual event sponsored by The Conference Forum, for clinical operation professionals to get the best access to innovative ideas, especially disruptive ones, to advance drug development with a view to reducing the burden to patients and investigators. Attendees leave DPHARM with a host of ideas to solve current challenges in clinical trials and better prepared for the expectations for 21st Century drug development with an extended network of strategic level thinkers.
At 11:30 on September 22, Dr. Jules Mitchel, CEO of Target Health LLC will present a talk entitled On Learnings From a COVID-19 Study that Used E-Informed Consent and Realtime Direct Data Capture. The following is a summary of what to expect.
Doing research in the time of COVID-19 is like doing a study in a war zone. Patient encounters are limited and the use of paper informed consent documents (eICD's) and paper source records for initial data capture in the ICU or COVID-19 unit are not allowed. Tablets secured in a sterile environment connected to the internet are acceptable which allows for electronic signatures and remote data capture. In this case example, while these paperless tools were not universally accepted in an ongoing COVID-19 study, there was clear adoption by some of the sites.
For more information about Target Health, contact Kathleen Kane Tremmel, Vice President, Business Development. For those who have been working with Warren Pearlson, Director, New Business Development, please continue to do so. For additional information about software tools for paperless clinical trials, please also feel free to contact Dr. Jules T. Mitchel. The Target Health software tools are designed to partner with both CROs and Sponsors. Also visit the Target Health Eating Website to see all of the fantastic recipes since 2012.
Joyce Hays, Founder and Editor in Chief of On Target
Dr. Jules T. Mitchel, Editor